Delving into the Latest Updates on Cat allergy immunotherapy(Circassia Group Plc) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Cat allergen vaccine, Cat allergy immunotherapy, Cat-PAD

+ [3]

Target-

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

AsthmaCat allergy (disorder)Conjunctivitis+ [3]

Originator Organization

Niox Group Plc

Active Organization-

Inactive Organization

Circassia Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Allergen immunotherapies are often successful at desensitizing allergic patients but can require life-long dosing and suffer from frequent adverse events including instances of systemic anaphylaxis, leading to poor patient compliance and high cost. Allergen vaccines, in turn, can generate more durable immunological allergen desensitization with far fewer doses. However, like immunotherapies, allergen vaccines are often highly reactogenic in allergic patients, hampering their use in therapeutic settings. In this work, we utilize a peptide-based self-assembling nanofiber platform to design allergen vaccines against allergen B-cell epitopes that do not elicit systemic anaphylaxis when administered subcutaneously to allergic mice. We show that, in contrast to protein vaccines, nanofiber vaccines prevent leakage of allergen material into the vascular compartment, a feature that likely underpins their reduced systemic reactogenicity. Further, we show that our allergen vaccine platform elicits therapeutic IgG antibody responses capable of desensitizing allergic mice to allergen-induced Type I hypersensitivity reactions. Finally, we have demonstrated a proof-of-concept for the therapeutic potential of nanofiber-based peanut allergen vaccines directed against peanut allergen-derived epitopes.

01 Mar 2023·ERJ Open Research

Adding a biologic to allergen immunotherapy increases treatment efficacy

Article

Author: Bożek, Andrzej ; Fischer, Andreas ; Canonica, Giorgio Walter ; Bogacz-Piaseczynska, Agnieszka

BackgroundThe application of allergen immunotherapy (AIT) in combination with biological agents has been found to increase both the safety and efficacy of the desensitisation procedure in patients with food and insect venom allergy. The aim of our study was to compare the effectiveness of AIT in patients with house dust mite (HDM)-driven asthma treated with and without omalizumab.Materials and methodsThe study was a placebo-controlled, three-armed, randomised, parallel-group, multicentre trial that included 52 patients with HDM-driven asthma. Only patients with monosensitisation to HDM were included. The study compared three patterns of therapy: omalizumab alone, HDM subcutaneous immunotherapy (SCIT-HDM)+ omalizumab, and SCIT alone. The main outcomes were evaluate the Asthma Control Questionnaire (ACQ) score, number of asthma exacerbations and reduction in the daily dose of inhaled steroids during 12 months of observation.ResultsAll variants of therapy led to significantly improved ACQ scores and reduction of asthma exacerbations in all study groups after 12 months of treatment. A statistically significant reduction in the daily doses of inhaled corticosteroids in the group with omalizumab alone (650±150 µgversus500±50 µg for p=0.003) or SCIT-HDM+omalizumab (550±250 µgversus375±75 µg for p=0.001) was observed, favouring the latter group.ConclusionThe efficacy of AIT for HDM-driven asthma is significantly increased by the combination of allergen vaccine with omalizumab.

06 Nov 2022·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[Expert consensus on diagnosis, treatment and prevention of allergic diseases (Part Ⅱ)].

Article

This article is the second part of the consensus. The principle of allergic diseases treatment is "combination of prevention and treatment, four in one":environmental control can avoid or reduce allergens, which is the first choice; allergen vaccine desensitization treatment is a cause-response treatment and has been considered as the first-line treatment; targeting drugs to block allergy or anti-allergy drugs to control symptoms is a commonly used symptomatic treatment method, which needs to be used with reference to the management of chronic diseases; Health education can change patients' misconceptions, improve their initiative and compliance, change their behavior, and improve the efficacy.

100 Deals associated with Cat allergy immunotherapy(Circassia Group Plc)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	Phase 3	US	Circassia Ltd.	01 May 2016
Rhinitis, Allergic, Seasonal	Phase 3	US	Circassia Ltd.	01 May 2016
Rhinitis, Allergic, Seasonal	Phase 3	US	Circassia Ltd.	01 May 2016
Cat allergy (disorder)	Phase 3	-	Circassia Ltd.	01 Feb 2014
Ragweed Sensitivity	Phase 3	CA	Circassia Ltd.	01 Apr 2009
Rhinoconjunctivitis	Phase 3	CA	Circassia Ltd.	01 Apr 2009
Asthma	Phase 3	CA	Circassia Ltd.	01 Mar 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01620762 (CTgov)	Phase 3	Rhinoconjunctivitis	1,408	Placebo	yjfagelvbf(mlkkgjefzs) = blnsdjqidu wgyvcnzjyc (szqsowvwmv, xvphapjnzk - mtyeumzkgp) View more	-	14 May 2018
NCT02040844 (CTgov)	Phase 3	Cat allergy (disorder)	430	placebo (Cat-PAD Treatment 1 (1 Course))	fxsrjwztag(xjpgjrovuf) = iktfjunjmu xbdotkhuij (ilauakrkch, oxjzvjdcxp - mdteyvrwsz) View more	-	14 May 2018
NCT02040844 (CTgov)	Phase 3	Cat allergy (disorder)	430	Cat-PAD (Cat-PAD Treatment (2 Courses))	fxsrjwztag(xjpgjrovuf) = orxkbsodei xbdotkhuij (ilauakrkch, kcbtffaofj - bmolafccbd) View more	-	14 May 2018
ASCO2004	Phase 1/2	Multiple Myeloma	15	PAD combination	uxdejzhjrk(yghgexanvo) = zubpexystp hrhlirmxzu (uyvctnguln ) View more	-	15 Jul 2004